Cyberkinetics Neurotechnology Systems, Inc., Strengthens Management Team with Jonathan T. Hartmann, Vice President of Sales and Marketing.

FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN; "Cyberkinetics") today announced that its Board of Directors has appointed Jonathan T. Hartmann to the newly established position of Vice President of Sales and Marketing.

In this role, Mr. Hartmann will develop sales and distribution strategies for the Company's product lines. His initial focus will be to lead the ongoing launch of Cyberkinetics' FDA 510(K)-approved NeuroPort(TM) Neural Monitoring System ("NeuroPort System"; "NeuroPort"). He will also prepare the market for the launch of the Company's Andara Oscillating Field Stimulator(TM) Device ("Andara OFS Device") for neural repair of spinal cord injuries. The Company anticipates that it will file for HDE (Humanitarian Device Exemption) approval of the Andara OFS Device in 2006.

"Jonathan has a terrific management background with expertise in selling a wide range of medical products -- from implantable pacemakers to capital equipment," stated Timothy R. Surgenor, President and Chief Executive Officer at Cyberkinetics. "His track record in building and leading successful sales teams rounds out our management team and positions us for growth in clinical sales."

Immediately prior to joining Cyberkinetics, Hartmann was with Guidant Corporation, where he served as a Regional Manager with the Cardiac Rhythm Management Division. Previously, Hartmann was Director of Corporate Marketing and Strategic Ventures at Guidant where he was responsible for development of patient and referral physician marketing strategy, strategic partnerships, corporate brand implementation, and new ventures involving healthcare technology for all four Guidant business units.

Hartmann also served as Market Development Manager at Urologix, Inc., a medical device company, where he was responsible for product launch and sales strategy for the company's proprietary microwave technology designed to treat benign prostate hyperplasia and the launch of the Targis System in the United States market. Prior to that, he worked in a variety of sales and marketing positions in the medical device industry, including roles at W.L. Gore and Associates and US Surgical Corporation.

Hartmann earned his Masters degree in Business Administration at the Harvard University Graduate School of Business Administration in Boston, Massachusetts and his Bachelor of Science degree at St. Lawrence University in Canton, New York.

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: the FDA 510(K)-approved NeuroPort(TM) System, a neural monitor designed for acute inpatient applications and labeled for temporary (less than 30 days) recording and monitoring of brain electrical activity; the Andara Oscillating Field Stimulator(TM) (OFS) Device, designed to stimulate regeneration of the spinal cord; and the BrainGate(TM) System, designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement. Additional Information about Cyberkinetics' acquisition of Andara Life Sciences, Inc., including an investor fact sheet, is available at Cyberkinetics website in the "Media Room" at http://www.cyberkineticsinc.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.